CellCarta and physIQ join forces on personalised vaccines study

CellCarta and physIQ announce collaboration on study that could “revolutionise vaccine development.”  

The study will monitor individual differences in physiologic changes associated with immune system activation in patients receiving vaccinations, including COVID-19 vaccinations.  

A combination of blood samples and wearable, medical-grade biosensors will allow researchers to continuously monitor and capture remote patient physiology data, establishing individual baselines to detect subtle changes within hours after vaccination.  

This precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness.

The study is expected to provide the most detailed evaluation of vaccine-induced reactogenicity (capacity of a vaccine to produce common, expected adverse reactions) and immunogenicity (the ability of cells/tissues to provoke an immune response) to date. 

Chief Medical Officer of physIQ, Steven Steinhubl, says the goal is to accelerate the therapeutic development of personalised vaccine regimens, where real-time data capture would allow healthcare providers to identify and minimise adverse reactions early.  

Findings from the study are expected to be released in the coming months.